Registry of Patients With MPNs in Taiwan

Status Active, not recruiting

Clinical Trial Summary

Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies with great variation in reported patient life expectancy and are characterized by a relatively indolent course which can be complicated by thromboembolic events and transformation to acute myeloid leukemia (AML). The MPNs in the 2016 World Health Organization (WHO) classification of myeloid neoplasms consist of polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) including prefibrotic/early stage and over fibrotic stage, chronic myeloid leukemia, other (rare) disorders such as chronic neutrophilic leukemia and chronic eosinophilic leukemia and MPN unclassifiable (MPN-U). The prevalence and genetic characteristics of patients with MPNs in Taiwan are still unknown. Molecular tests which are required for the diagnosis of MPNs are not available in many hospitals which hamper the accurate diagnosis and subtype classification of MPNs. Moreover, the information of current therapeutic strategy for MPNs in most medical centers in Taiwan is also not available. The purpose of this MPN registry is to collect clinical data, molecular characteristics, treatment details and response to therapy, occurrence of complications during the course, disease progression to secondary myelofibrosis from PV or ET and secondary AML (sAML) transformation as well as survival. The clinical and molecular data including the high molecular risk (HMR) genes will be examined and correlated with treatment outcomes in Taiwanese MPN patients. The Molecular Diagnostic Laboratory at Chang Gung Memorial Hospital-Linkou is a College of American Pathologists (CAP)-accredited lab which provides high quality of molecular genetic tests for hematologic malignancies. The three driver gene mutations are the major criteria for the diagnosis of MPN, the methodologies of mutational analyses have been well set up for the clinical use in this lab. In addition, this lab is also equipped with facilities for the detection of mutated genes which were recently identified as HRM category (presence of any of ASXL1, EZH2, SRSF2, IDH1 or IDH2), and mutations of other epigenetic regulators or splicing factors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03618485
Study type	Observational [Patient Registry]
Source	Chang Gung Memorial Hospital
Contact
Status	Active, not recruiting
Phase
Start date	April 1, 2017
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Recruiting	`NCT05936359` - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Phase 1
Completed	`NCT02084563` - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms	Phase 2
Recruiting	`NCT04339400` - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms	Phase 1
Completed	`NCT02125318` - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders	Phase 2
Not yet recruiting	`NCT06291987` - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	Phase 1
Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
Completed	`NCT03075826` - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms	Phase 2
Recruiting	`NCT02823210` - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Not yet recruiting	`NCT06313593` - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms	Phase 1
Active, not recruiting	`NCT05444530` - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms	Phase 1
Active, not recruiting	`NCT03912064` - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	Phase 1
Terminated	`NCT02393248` - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Phase 1/Phase 2
Completed	`NCT02076191` - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	Phase 1/Phase 2
Active, not recruiting	`NCT04761770` - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	Phase 2
Recruiting	`NCT06034002` - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms	Phase 1
Completed	`NCT00949364` - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage	Phase 2
Completed	`NCT00053196` - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer	Phase 2
Terminated	`NCT01668173` - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET	Phase 2